Aerovate Therapeutics Inc Stock

$7.72

3.98%

Nasdaq, Tue, May 20 2025

ISIN

US0080641071

Symbol

AVTE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aerovate Therapeutics Inc Stock price

$7.72

-791.34 99.03% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.30 3.98%

ISIN

US0080641071

Symbol

AVTE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$7.11m
Enterprise Value	$-68.79m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.38
P/B ratio (TTM) P/B ratio	0.09
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-53.37m
Free Cash Flow (TTM) Free Cash Flow	$-49.90m
Cash position	$76.21m
EPS (TTM) EPS	$-59.44
P/E forward	negative
Short interest	1.15%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Aerovate Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Aerovate Therapeutics Inc forecast:

3x Buy

75%

1x Hold

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Aerovate Therapeutics Inc forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Aerovate Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.26 0.26	160% 160% -
Gross Profit	-0.26 -0.26	160% 160% -
- Selling and Administrative Expenses	20 20	14% 14% -
- Research and Development Expense	33 33	53% 53% -
EBITDA	-53 -53	40% 40% -
- Depreciation and Amortization	0.26 0.26	160% 160% -
EBIT (Operating Income) EBIT	-53 -53	40% 40% -
Net Profit	-49 -49	40% 40% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aerovate Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

23 days ago

Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCO...

Neutral

PRNewsWire

●

30 days ago

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass. , April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger.

Neutral

PRNewsWire

●

about one month ago

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass. , April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to th...

More Aerovate Therapeutics Inc News

Company Profile

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focus on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake in July 27, 2018 and is headquartered in Boston, MA.

Head office	United States
CEO	Tom Frohlich
Employees	30
Founded	2018
Website	www.aerovatetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now